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DrRaphael Bueno (Boston, Mass). I would like to congratulate
you and the rest of the authors from Roswell Park on your success-
ful presentation of this work. I have a few questions. First, you note
that the gold standard kept shifting. You show that the gamma
probe approach with fludeoxyglucose (FDG) is not sufficiently ac-
curate to identify positive lymph nodes when the gold standard is
real-time polymerase chain reaction (RT-PCR), but how good was
it when the gamma probe results were compared with the poistron
emission tomography–computed tomography (PET-CT) scan or
the immunohistology of the lymph nodes?
Dr Chukwumere Nwogu (Buffalo, NY). You’re asking how
good was the gamma probe in detecting disease?
Dr Bueno. RT-PCR is not something that everybody in the
world does. What everybody in the world does is they get a PET
scan and they do histology. Sowhen you look at your gamma probe
results, you’re comparing them to known, defined things; that is,
the PET scan and the histology report. How good was it then in
terms of sensitivity, specificity, and accuracy?
Dr Nwogu. It was very sensitive in detecting disease. The
gamma probe detected activity in all the lymph nodes that were
positive using standard histology techniques. The false-positiveThe Journal of Thoracic and Carate was very high due to inflammation. That’s the challenge
with using FDG. We definitely need better radioisotopes that
will be more specific. Radioisotopes like fluorothymidine are
more specific; however, they are less sensitive. We know that
a lot of our patients have missed nodal disease, and there are re-
ports indicating a difference in survival based on the presence of
RT-PCR positive lymph nodes and negative lymph nodes.
Dr Bueno. My next question is about your patients. About
half ended up with positive lymph nodes by RT-PCR, which sug-
gests to me that most of the cases were not TNM Classification
System of Malignant Tumors (TNM) stage T1 but might have
been stage T2 or bigger T1s. If that’s true, did you stage them
up front with mediastinoscopy, or why did you choose to go
with surgery?
Dr Nwogu.We staged the disease of all these patients with me-
diastinoscopy. There were only 2 patients in our overall cohort
with positive mediastinal nodes and we did not proceed with sur-
gical resection in those cases. Most of these patients had stage T1
and T2 lesions. They all were diagnosed with clinical stage I or II
disease before surgery.
Dr Bueno. You seem to prefer RT–PCR as your gold standard
here, as we just discussed. Do you currently use it clinically, or do
you just use it as a research tool? It’s not a truly validated, worked-
out technique, as attractive as it sounds in this study.
Dr Nwogu. We are just using it for research at this point.
However, the few patients whowere diagnosed with immunohisto-
chemically positive occult disease were referred for a conversation
with a medical oncologist about getting adjuvant therapy. If we
show that there is a difference in survival between patients who
have RT–PCR-diagnosed positive nodes and those who don’t,
we have to do a clinical trial to justify adjuvant therapy.We haven’t
gotten there yet.
Dr Bueno. Finally, what this very nicely illustrates is that
RT–PCR, which is a little challenging for the pathology labs of
most hospitals, is nicely recapitulated in staining with vascular en-
dothelial growth factor (VEGF). Essentially that’s what you would
expect to do. So are you planning to move in that direction, either
to create an isotope for VEGF or have pathologists stain the nodes
for one of the VEGFs as a predictor of lymph node status?
Dr Nwogu.We haven’t done that yet, but that’s a fantastic sug-
gestion and I would definitely like to explore that.
Dr Richard J. Finley (Vancouver, BC, Canada). I would like to
ask 1 question about the size of the lymph nodes. Why were you
able to pick up so many more lymph nodes with the gamma probe
versus the regular PET–CT scan?
Dr Nwogu. I think in some ways it’s an unfair comparison be-
tween PET–CTand the gamma probe. With PET–CT scans you’re
looking at a broad view of the thorax and essentially a lot of the
lymph nodes that are in the vicinity of the primary tumor are going
to be overshadowed by the activity of the primary tumor. Most of
these patients had stage I disease. The PET–CT is most likely not
going to detect small deposits of cancer in the lymph nodes below
a threshold of 5 to 6 mm. However, the gamma probe can be put
directly on the lymph node, away from the patient. It can thus de-
tect smaller volume of disease. So by its very nature, the gamma
probe will have an advantage.
Dr Gunda Leschber (Berlin, Germany). Do you think the high
rate of positive lymph nodes could explain why somany patients inrdiovascular Surgery c Volume 145, Number 3 707
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Sthe early stages of disease do not do well in the end? The survival
rate for patients diagnosed with stage I disease is still not 100%.
Do you think that could be an explanation?
DrNwogu.Yes. It has been shown inmultiple studies, including
the recently published Z0040 study results fromAmerican College
of Surgeons Oncology Group (ACOSOG), that there is a high prev-
alence of occult metastatic lymph node disease. In that study they
showed a prevalence of 22% for occult lymph node disease, and
that was with immunohistochemistry. RT–PCR has been clearly
shown to be more sensitive, so we know that there are many pa-
tients who have occult disease. How many of them are clinically
relevant is a little bit controversial, but research has shown that
there’s a decrease in survival. So in our case the RT–PCR test
was very sensitive in detecting occult disease.
Dr Yolanda Colson (Boston, Mass). You have to be really
careful about saying that a gamma probe has increased sensitiv-
ity. What it really is, is that it has a high false-positive rate be-
cause you have shine-through from the surrounding tumor.
Those are two different concepts. It’s not really high sensitivity708 The Journal of Thoracic and Cardiovascular Surgif it spreads everywhere. Clinically we think of this spread as
false positives.
How do you know that the VEGF that you’re detecting actually
pathologically means anything? Is it truly metastasis? You’re not
seeing it any other way that you have to detect it. Does it mean any-
thing or is it just a marker of inflammation in that node or new lym-
phatic pathways, but not necessarily metastasis?
Dr Nwogu. That’s a very good question. Given the fact that we
don’t have a really good gold standard to assess RT–PCR, what we
have to rely on is the recurrence rate. Our current median follow-
up is 12.6 months. Right now, we have too few events to really see
a statistical difference in recurrence rate between the patients with
RT–PCR negative nodes and the patients with RT–PCR positive
nodes, but when we have longer follow-up and more events, we
can determine if there is a difference in recurrence between the
2 groups of patients.
The detected gamma probe radioactivity was not from shine-
through from the primary tumor. The measurements were taken
after lymph nodes were dissected away from the lung.ery c March 2013
